UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D. C. 20549

 

FORM 10-Q

 

(Mark One)

 

 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended September 30, 20222023

 

OR

 

 

TRANSITION REPORT PURSUANT TO SECTION13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from           to          

 

NORTECH SYSTEMS INCORPORATED

 

Commission file number 0-13257

 

State of Incorporation: Minnesota

 

IRS Employer Identification No. 41-1681094

 

Executive Offices: 7550 Meridian Circle N., Suite # 150, Maple Grove, MN 55369

 

Telephone number: (952) 345-2244

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, par value $.01 per share

NSYS

NASDAQ Capital Market 

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulations S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).  Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company.  See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large Accelerated Filer ☐

 

Accelerated Filer ☐

Non-accelerated Filer☐Filer ☒

 

Smaller Reporting Company ☒

Emerging growth company ☐

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes ☐ No ☒

 

Number of shares of $.01 par value common stock outstanding at November 4, 20223, 2023 was 2,690,634.2,739,377.

   


1

 

 

TABLE OF CONTENTS

 

         

PART I - FINANCIAL INFORMATION 
   PAGE
 Item 1-Financial Statements 
   
  Condensed Consolidated Statements of Operations and Comprehensive Income3
    
  Condensed Consolidated Balance Sheets4
    
  Condensed Consolidated Statements of Cash Flows5-65
    
  Condensed Consolidated Statements of Shareholders’ Equity7
    
  Condensed Notes to Consolidated Financial Statements  8-198-21
   
 Item 2-Management's Discussion and Analysis of Financial Condition And Results of Operations20-2622-27
   
 Item 3-Quantitative and Qualitative Disclosures About Market Risk2728
   
 Item 4-Controls and Procedures2728
    
PART II - OTHER INFORMATION 
   
 Item 1-Legal Proceedings2829
   
 Item 1A.-Risk Factors2829
   
 Item 2-Unregistered Sales of Equity Securities, Use of Proceeds2829
   
 Item 3-Defaults on Senior Securities2829
   
 Item 4-Mine Safety Disclosures2829
   
 Item 5-Other Information2829
   
 Item 6-Exhibits2930
    
SIGNATURES 3031

 


2

 

PART I

ITEM 1. FINANCIAL STATEMENTS

NORTECH SYSTEMS INCORPORATED AND SUBSIDIARIESITEM 1.

CONDENSED CONSOLIDATEDFINANCIAL STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME

(UNAUDITED)

(IN THOUSANDS, EXCEPT SHARE DATA)

 

  

THREE MONTHS ENDED

  

NINE MONTHS ENDED

 
  

SEPTEMBER 30,

  

SEPTEMBER 30,

 
  

2022

  

2021

  

2022

  

2021

 
                 

Net Sales

 $35,276  $29,452  $98,505  $81,706 
                 

Cost of Goods Sold

  28,948   21,411   83,129   68,519 
                 

Gross Profit

  6,328   8,041   15,376   13,187 
                 
Operating Expenses                

Selling Expenses

  959   449   2,752   1,741 

General and Administrative Expenses

  2,949   2,045   8,346   7,247 

Research and Development Expenses

  475   141   1,154   348 

Restructuring Charges

  -   23   -   319 

Loss on Abandonment of Intangible Assets

  -   560   -   560 

Gain on Sale of Assets

  -   (93)  (15)  (176)
                 

Total Operating Expenses

  4,383   3,125   12,237   10,039 
                 

Income From Operations

  1,945   4,916   3,139   3,148 
                 
Other Expense                

Interest Expense

  (122)  (112)  (337)  (314)
                 

Income Before Income Taxes

  1,823   4,804   2,802   2,834 
                 

Income Tax Expense

  289   1,247   411   646 
                 

Net Income

 $1,534  $3,557  $2,391  $2,188 
                 
Net Income Per Common Share:                
                 

Basic (in dollars per share)

 $0.57  $1.33  $0.89  $0.82 

Weighted Average Number of Common Shares Outstanding - Basic (in shares)

  2,686,884   2,665,682   2,683,594   2,662,066 
                 

Diluted (in dollars per share)

 $0.53  $1.24  $0.83  $0.78 

Weighted Average Number of Common Shares Outstanding - Diluted (in shares)

  2,899,526   2,880,073   2,886,073   2,806,958 
                 
Other comprehensive income                

Foreign currency translation

  (365)  (5)  (604)  20 

Comprehensive income, net of tax

 $1,169  $3,552  $1,787  $2,208 

NORTECH SYSTEMS INCORPORATED AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME

(UNAUDITED)

(IN THOUSANDS, EXCEPT SHARE DATA)

  

THREE MONTHS ENDED

  

NINE MONTHS ENDED

 
  

SEPTEMBER 30,

  

SEPTEMBER 30,

 
  

2023

  

2022

  

2023

  

2022

 
                 

Net Sales

 $33,369  $35,276  $103,278  $98,505 
                 

Cost of Goods Sold

  28,050   28,948   87,001   83,129 
                 

Gross Profit

  5,319   6,328   16,277   15,376 
                 

Operating Expenses

                

Selling Expenses

  923   959   2,766   2,752 

General and Administrative Expenses

  2,958   2,949   9,328   8,346 

Research and Development Expenses

  314   475   907   1,154 

Gain on Sale of Assets

  -   -   -   (15)
                 

Total Operating Expenses

  4,195   4,383   13,001   12,237 
                 

Income From Operations

  1,124   1,945   3,276   3,139 
                 

Other Expense

                

Interest Expense

  (130)  (122)  (365)  (337)
                 

Income Before Income Taxes

  994   1,823   2,911   2,802 
                 

Income Tax (Benefit) Expense

  (213)  289   389   411 
                 

Net Income

 $1,207  $1,534  $2,522  $2,391 
                 

Net Income Per Common Share:

                
                 

Basic (in dollars per share)

 $0.44  $0.57  $0.93  $0.89 

Weighted Average Number of Common Shares Outstanding - Basic (in shares)

  2,737,895   2,686,884   2,716,166   2,683,594 
                 

Diluted (in dollars per share)

 $0.42  $0.53  $0.87  $0.83 

Weighted Average Number of Common Shares Outstanding - Diluted (in shares)

  2,888,679   2,899,526   2,887,889   2,886,073 
                 

Other comprehensive income

                

Foreign currency translation

  (77)  (365)  (318)  (604)

Comprehensive income, net of tax

 $1,130  $1,169  $2,204  $1,787 

 

See Accompanying Condensed Notes to Condensed Consolidated Financial Statements

 

3

 

 

NORTECH SYSTEMS INCORPORATED AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS 

(IN THOUSANDS, EXCEPT SHARE DATA)

 

 

SEPTEMBER 30,

 

DECEMBER 31,

  

SEPTEMBER 30,

 

DECEMBER 31,

 
 

2022

   2021(1)  

2023

  

2022(1)

 

 

(Unaudited)

     

(Unaudited)

    
ASSETS          
Current Assets      

Cash

 $1,300  $643  $699  $1,027 

Restricted Cash

 792  1,582  422  1,454 

Accounts Receivable, less allowances of $257 and $328

 15,497  14,548 

Accounts Receivable, less allowances of $316 and $334

 15,956  15,975 

Employee Retention Credit Receivable

 5,209  5,209  -  2,650 

Inventories, Net

 23,610  19,434  21,467  22,438 

Contract Assets

 9,886  8,698 

Prepaid Expenses and Other Current Assets

  1,851   1,660 

Contract Assets, less allowances of $22 and $0

 11,746  9,982 

Income Taxes Receivable

 388  - 

Prepaid Expenses

  1,916   1,334 

Total Current Assets

  58,145   51,774   52,594   54,860 
      

Property and Equipment, Net

 6,457  5,833  6,135  6,408 

Operating Lease Assets

 8,079  8,983  6,955  7,850 

Other Intangible Assets, Net

  433   501   303   422 

Total Assets

 $73,114  $67,091  $65,987  $69,540 
      

LIABILITIES AND SHAREHOLDERS' EQUITY

            
Current Liabilities      

Current Portion of Finance Lease Obligations

 $390  $601  $401  $390 

Current Portion of Operating Lease Obligations

 1,113  1,043  996  1,155 

Accounts Payable

 14,701  12,710  13,099  14,792 

Accrued Payroll and Commissions

 5,116  4,045  3,976  4,803 

Income Taxes Payable

 27  733 

Customer Deposits

 3,870  2,936  3,861  3,515 

Other Accrued Liabilities

  1,380   971   839   1,010 

Total Current Liabilities

  26,570   22,306   23,199   26,398 
      
Long-Term Liabilities      

Long Term Line of Credit

 9,826  8,959  4,611  6,853 

Long Term Finance Lease Obligations, Net

 639  916  261  565 

Long-Term Operating Lease Obligations, Net

 7,797  8,695  6,835  7,549 

Deferred Income Taxes

 278  - 

Other Long-Term Liabilities

  99   104   95   95 

Total Long-Term Liabilities

  18,361   18,674   12,080   15,062 

Total Liabilities

  44,931   40,980   35,279   41,460 
      
Commitments and Contingencies        
      
Shareholders' Equity      

Preferred Stock, $1 par value; 1,000,000 Shares Authorized: 250,000 Shares Issued and Outstanding

 250  250  250  250 

Common Stock - $0.01 par value; 9,000,000 Shares Authorized: 2,683,513 and 2,672,064 Shares Issued and Outstanding, respectively

 27  27 

Common Stock - $0.01 par value; 9,000,000 Shares Authorized: 2,739,377 and 2,690,633 Shares Issued and Outstanding, respectively

 27  27 

Additional Paid-In Capital

 16,247  15,962  16,801  16,347 

Accumulated Other Comprehensive (Income) Loss

 (548) 56 

Accumulated Other Comprehensive Loss

 (688) (370)

Retained Earnings

  12,207   9,816   14,318   11,826 

Total Shareholders' Equity

  28,183   26,111   30,708   28,080 

Total Liabilities and Shareholders' Equity

 $73,114  $67,091  $65,987  $69,540 

(1) The balance sheet at December 31, 2022 has been derived from the audited financial statements at that date

 

See Accompanying Condensed Notes to Condensed Consolidated Financial Statements

(1) The condensed consolidated balance sheet at December 31, 2021 has been derived from the audited financial statements at that date

 

4

 

NORTECH SYSTEMS INCORPORATED AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

(IN THOUSANDS)

 

NORTECH SYSTEMS INCORPORATED AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

(IN THOUSANDS)

 

NINE MONTHS ENDED

  

NINE MONTHS ENDED

 
 

SEPTEMBER 30,

  

SEPTEMBER 30

 
 

2022

  

2021

  

2023

  

2022

 
CASH FLOWS FROM OPERATING ACTIVITIES    

CASH FLOWS PROVIDED BY OPERATING ACTIVITIES

    

Net Income

 $2,391  $2,188  $2,522  $2,391 
Adjustments to Reconcile Net Income to Net Cash  

Provided By (Used In) Operating Activities:

 

Provided By Operating Activities:

 

Depreciation and Amortization

 1,440  1,506  1,539  1,440 

Compensation on Stock-Based Awards

 234  201  299  234 

Change in Accounts Receivable Allowance

 (71) 18 

Deferred Income Taxes

 288  - 

Change in Inventory Reserves

 (54) (959) (8) (54)

Loss on Abandonment of Intangible Asset

 -  560 

Gain on Disposal of Property and Equipment

 (15) (176)

Other, Net

 (169) (86)
Changes in Current Operating Items  

Accounts Receivable

 (1,115) 1,686  (162) (1,115)

Employee Retention Credit Receivable

 -  (5,209) 2,650  - 

Inventories

 (4,402) (5,755) 899  (4,402)

Contract Assets

 (1,188) (2,246) (1,780) (1,188)

Prepaid Expenses and other Curent Assets

 (213) (276)

Income Taxes

 (67) 708 

Prepaid Expenses

 (588) (213)

Income Tax Receivable

 (388) (22)

Income Tax Payable

 (696) (45)

Accounts Payable

 1,659  2,901  (1,636) 1,659 

Accrued Payroll and Commissions

 1,071  1,537  (810) 1,071 

Customer Deposits

 345  934 

Other Accrued Liabilities

  1,330   464   (124)  396 

Net Cash Provided By (Used In) Operating Activities

  1,000   (2,852)

Net Cash Provided By Operating Activities

  2,181   1,000 
  
CASH FLOWS FROM INVESTING ACTIVITIES        

Proceeds from Sale of Property and Equipment

 15  626  -  15 

Purchase of Intangible Asset

 (43) (49) -  (43)

Purchases of Property and Equipment

  (1,687)  (1,198)  (1,121)  (1,687)

Net Cash Used In Investing Activities

  (1,715)  (621)  (1,121)  (1,715)
  
CASH FLOWS FROM FINANCING ACTIVITIES        

Net Change in Line of Credit

 857  2,681 

Principal Payments on Long-Term Debt

 -  (873)

Proceeds from Line of Credit

 95,783  88,673 

Payments to Line of Credit

 (98,035) (87,816)

Principal Payments on Financing Leases

 (336) (492) (291) (326)

Debt Issuance Costs

 10  - 

Stock Option Excercises

  51   36   155   51 

Net Cash Provided By Financing Activities

  582   1,352 

Net Cash (Used In) Provided By Financing Activities

  (2,388)  582 
  

Net Change in Cash and Cash Equivalents

 (133) (2,121)

Cash and Cash Equivalents - Beginning of Period

  2,225   3,564 

Cash and Cash Equivalents - End of Period

 $2,092  $1,443 

Effect of Exchange Rate Changes on Cash

  (32)  - 
 

Net Change in Cash and Restricted Cash

 (1,360) (133)

Cash and Restricted Cash - Beginning of Year

  2,481   2,225 

Cash and Restricted Cash - End of Period

 $1,121  $2,092 
  
Reconciliation of cash and restricted cash reported within the consolidated balance sheets  

Cash

 $1,300  $444  $699  $1,300 

Restricted Cash

  792   999   422   792 

Total Cash and restricted cash reported in the consolidated statements of cash flows

 $2,092  $1,443  $1,121  $2,092 

 

See Accompanying Condensed Notes to Condensed Consolidated Financial Statements

 


5

 

NORTECH SYSTEMS INCORPORATED AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

(IN THOUSANDS)

 

 

NINE MONTHS ENDED

  

NINE MONTHS ENDED

 
 

SEPTEMBER 30,

  

SEPTEMBER 30

 
 

2022

  

2021

  

2023

  

2022

 

Supplemental Disclosure of Cash Flow Information:

  

Cash Paid During the Period for Interest

 $328  $220  $388  $328 

Cash Paid (Refunded) During the Period for Income Taxes

 122  (114)

Cash Paid During the Period for Income Taxes

 1,242  122 
  

Supplemental Noncash Investing and Financing Activities:

  

Property and Equipment Purchases in Accounts Payable

 332  -  23  332 

Property Acquired Under Operating Lease

 -  858 

 

See Accompanying Condensed Notes to Condensed Consolidated Financial Statements

 


6

 

 

NORTECH SYSTEMS INCORPORATED AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY

(UNAUDITED)

(IN THOUSANDS)

 

       Accumulated            

Accumulated

    

 

 
     Additional Other          

Additional

 

Other

 

 

    
 Preferred Common Paid-In Comprehensive Retained Total Shareholders'  

Preferred

 

Common

 

Paid-In

 

Comprehensive

 Retained  Total Shareholders'   
 Stock Stock Capital Loss Earnings Equity  

Stock

  

Stock

  

Capital

  

Loss

  

Earnings

  

Equity

 
              

BALANCE JUNE 30, 2021

 $250  $27  $15,862  $(12) $1,293  $17,420 

Net Income

 -  -  -  -  3,557  3,557 

Foreign currency translation adjustment

 -  -  -  (5) -  (5)

Stock option exercises

 -  -  36  -  -  36 

Compensation on stock-based awards

  -   -   28   -   -   28 
 

BALANCE SEPTEMBER 30, 2021

 $250  $27  $15,926  $(17) $4,850  $21,036 
 

BALANCE DECEMBER 31, 2020

 $250  $27  $15,816  $(37) $2,662  $18,718 

Net Income

 -  -  -  -  2,188  2,188 

Foreign currency translation adjustment

 -  -  -  20  -  20 

Stock option exercises

 -  -  36  -  -  36 

Compensation on stock-based awards

  -   -   74   -   -   74 
 

BALANCE SEPTEMBER 30, 2021

 $250  $27  $15,926  $(17) $4,850  $21,036 
 

BALANCE JUNE 30, 2022

 $250  $27  $16,136  $(183) $10,673  $26,903  $250  $27  $16,136  $(183) $10,673  $26,903 

Net Income

 -  -  -  -  1,534  1,534  -  -  -  -  1,534  1,534 

Foreign currency translation adjustment

 -  -  -  (365) -  (365)

Foreign Currency Translation Adjustment

 -  -  -  (365) -  (365)

Stock option exercises

 -  -  18  -  -  18  -  -  18  -  -  18 

Compensation on stock-based awards

  -   -   93   -   -   93 

Compensation on Stock-Based Awards

  -   -   93   -   -   93 
              

BALANCE SEPTEMBER 30, 2022

 $250  $27  $16,247  $(548) $12,207  $28,183  $250  $27  $16,247  $(548) $12,207  $28,183 
              

BALANCE DECEMBER 31, 2021

 $250  $27  $15,962  $56  $9,816  $26,111  $250  $27  $15,962  $56  $9,816  $26,111 

Net Income

 -  -  -  -  2,391  2,391  -  -  -  -  2,391  2,391 

Foreign currency translation adjustment

 -  -  -  (604) -  (604)

Stock option exercises

 -  -  51  -  -  51 

Compensation on stock-based awards

  -   -   234   -   -   234 

Foreign Currency Translation Adjustment

 -  -  -  (604) -  (604)

Compensation on Stock-Based Awards

 -  -  51  -  -  51 

Stock Option Exercises

  -   -   234   -   -   234 
              

BALANCE SEPTEMBER 30, 2022

 $250  $27  $16,247  $(548) $12,207  $28,183  $250  $27  $16,247  $(548) $12,207  $28,183 
             

BALANCE JUNE 30, 2023

 $250  $27  $16,712  $(611) $13,111  $29,489 

Net Income

 -  -  -  -  1,207  1,207 

Foreign Currency Translation Adjustment

 -  -  -  (77) -  (77)

Stock Option Exercises

 -  -  9  -  -  9 

Compensation on Stock-Based Awards

  -   -   80   -   -   80 
             

BALANCE SEPTEMBER 30, 2023

 $250  $27  $16,801  $(688) $14,318  $30,708 
             

BALANCE DECEMBER 31, 2022

 $250  $27  $16,347  $(370) $11,826  $28,080 

Net Income

 -  -  -  -  2,522  2,522 

Foreign Currency Translation Adjustment

 -  -  -  (318) -  (318)

Stock Option Exercises

 -  -  155  -  -  155 

Compensation on Stock-Based Awards

 -  -  299  -  -  299 

Cumulative Adjustment Related to the Adoption of ASC 326

  -   -   -   -   (30)  (30)
             

BALANCE SEPTEMBER 30, 2023

 $250  $27  $16,801  $(688) $14,318  $30,708 

 

See Accompanying Condensed Notes to Condensed Consolidated Financial Statements

 

7

 

CONDENSED NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(DOLLARS IN THOUSANDS, EXCEPT SHARE AND PER SHARE DATA)
(UNAUDITED)

 

 

NOTE 1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements for the interim periods have been prepared in accordance with Generally Accepted Accounting Principles in the United States of America (“GAAP”) for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission. Accordingly, they do not include all of the financial information and footnotes required by GAAP for complete financial statements, although we believe the disclosures are adequate to make the information presented not misleading. It is suggested that these condensed consolidated financial statements be read in conjunction with the consolidated financial statements and the notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2021.2022. The operating results for the interim periods presented are not necessarily indicative of the results expected for the full year or for any other interim period. In our opinion, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included.

 

The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. In preparing these condensed consolidated financial statements, we have made our best estimates and judgments of certain amounts included in the condensed consolidated financial statements, giving due consideration to materiality. Changes in the estimates and assumptions used by us could have a significant impact on our financial results, since actual results could differ from those estimates.

 

Principles of Consolidation

The condensed consolidated financial statements include the accounts of Nortech Systems Incorporated and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated.

 

Revenue Recognition

Our revenue is comprised of product, engineering services and repair services. All revenue is recognized when the Company satisfies its performance obligation(s) under the contract by transferring the promised product or service to our customer either when (or as) our customer obtains control of the product or service, with the majority of our revenue being recognized over time including goods produced under contract manufacturing agreements and services revenue. A performance obligation is a promise in a contract to transfer a distinct product or service to a customer. A contract’s transaction price is allocated to each distinct performance obligation. The majority of our contracts have a single performance obligation. Revenue is recorded net of returns, allowances and customer discounts. Our net sales for services were less than 10% of our total sales for all periods presented, and accordingly, are included in net sales in the Condensed Consolidated Statements of Operations and Comprehensive Income (Loss).Income. Sales, value add, and other taxes collected from customers and remitted to governmental authorities are accounted for on a net (excluded from revenues) basis. Shipping and handling costs charged to our customers are included in net sales, while the corresponding shipping expenses are included in cost of goods sold. Customer deposits represent cash received in advance of revenue earned.

 

8

 

Stock-Based Awards

 

Stock Options

In May 2017, the shareholders approved the 2017 Stock Incentive Plan which authorized the issuance of 350,000 shares. AnSubsequent to this approval, an additional 50,000 and 175,000325,000 shares werehave been authorized by the shareholders in March 2020shareholders.

We granted 25,000 and May 2022,54,000 service-based stock options during the three and nine months ended September 30, 2023, respectively. The weighted-average grant-date fair value of options granted during the three and nine months ended September 30, 2023 was $6.13 and $5.88, respectively. There were no market-based stock options granted during the three and nine months ended September 30, 2023.

 

We granted 0 and 21,000 market conditionmarket-based stock options to our Chief Executive Officer during the three and nine months ended September 30, 2022, respectively. The market condition options vest if certain stock prices are exceeded between February 27, 2024 and February 27, 2028. We granted 3,000 and 69,000 service-based options during the three and nine months ended September 30, 2022, respectively. Total option grants for the three and nine months ended September 30, 2022 were 3,000 and 90,000, respectively. There were 27,000

Total compensation expense related to stock options granted duringwas $42 and $184 for the three and nine months ended September 30, 2021.

2023, respectively. Total compensation expense related to stock options was $62 and $168 for the three and nine months ended September 30, 2022, respectively. Total compensation expense related to stock options was $28 and $74 for the three and nine months ended September 30, 2021, respectively. As of September 30, 2022,2023, there was $810$724 of unrecognized compensation which will vestbe recognized over the next 3.86a weighted average period of 3.8 years.

 

Following is the status of all stock options as of September 30, 2022:2023:

 

 

Shares

  

Weighted-

Average

Exercise Price

Per Share

  

Weighted-

Average

Remaining

Contractual

Term

(in years)

  

Aggregate

Intrinsic Value

(in thousands)

  

Shares

  

Weighted-

Average

Exercise Price

Per Share

  

Weighted-

Average

Remaining

Contractual

Term

(in years)

  

Aggregate

Intrinsic Value
(in thousands)

 

Outstanding - January 1, 2022

 387,500  $4.57  

Outstanding - January 1, 2023

 452,700  $5.97  

Granted

 90,000  11.13   54,000  9.63  

Exercised

 (19,800) 3.40   (38,244) 4.09  

Cancelled

  (8,000)  3.38       (43,956)  7.50  

Outstanding - September 30, 2022

  449,700  $5.93  7.10  $2,137 

Exercisable - September 30, 2022

  213,500  $3.95  5.90  $1,407 

Outstanding - September 30, 2023

  424,500  $6.45  6.48  $1,375 

Exercisable - September 30, 2023

  242,800  $4.44  5.16  $1,197 

 

Restricted Stock Units

During the three months and nine months ended September 30, 2022,2023, we granted 0 and 21,00018,000 restricted stock units (“RSUs”), respectively under our 2017 Stock Incentive Plan to non-employee directors which vest over two years. There were noThe RSUs outstanding prior togranted in the three and nine months ended September 30, 2022.2023 had an average grant price of $9.37 per share. Total compensation expense related to the RSUs werewas $38 and $115 for the three and nine months ended September 30, 2023, respectively. Total unrecognized compensation expense related to the RSUs was $154, which will vest over a weighted average period of 1.2 years.

9

During the three months and nine months ended September 30, 2022, we granted 0 and 21,000 restricted stock units, respectively to non-employee directors which vest over two years. Total compensation expense related to the RSUs was $31 and $66 for the three and nine months ended September 30, 2022, respectively. There was no compensation expense related to RSUs for the three and nine months ended September 30, 2021. Total unrecognized compensation expense related to the RSUs was $186, which will vest over the next 1.49 years. The RSUs granted in the nine months ended September 30, 2022 had an average grant price of $12.00 per share with a weighted average remaining contractual term of 9.48 years. No RSUs vested during the nine months ended September 30, 2022.

9

Equity Appreciation Rights Plan

In November 2010, the Board of Directors adopted the Nortech Systems Incorporated Equity Appreciation Rights Plan (“2010 Plan”). The total number of Equity Appreciation Right Units (“Units”) that can be issued under the 2010 Plan shall not exceed an aggregate of 1,000,000 Units as amended and restated on March 11, 2015. There were no units granted during the nine months ended September 30, 2022 or September 30, 2021.

 

The 100,000 units outstanding at December 31, 2021 were paid on March 29, 2022. There are no units outstandingFollowing is a status of all RSUs as of September 30, 2022. Total compensation expense related to the vested outstanding Units based on the estimated appreciation over their remaining terms was $13 and $127 for the three and nine months ended September 30, 2021, respectively.2023:

  

Shares

  

Weighted-

Average Grant

Date Fair

Value

  

Weighted-

Average

Remaining

Contractual

Term

(in years)

  

Aggregate

Fair Value
(in thousands)

 

Outstanding - January 1, 2023

  21,000  $12.00         

Granted

  18,000   9.37         

Vested

  (10,500)  12.00         

Forfeited

  (6,000)  10.93         

Outstanding - September 30, 2023

  22,500  $10.18   9.23  $208 

 

Net Income per Common Share

Basic net income per common share is computed by dividing net income by the weighted-average number of common shares outstanding. DilutedDilutive net income per common share assumes the exercise and issuance of all potential common stock equivalents in computing the weighted-average number of common shares outstanding, unless their effect is antidilutive. All stock options and restricted stock units, while outstanding, are considered common stock equivalents.

 

For the three and nine months ended September 30, 2022,2023, stock options of 212,643150,783 and 202,479,171,723, respectively were included in the computation of diluted net income per common share as their impact were dilutive. For the three and nine months ended September 30, 2021,2022, stock options of 214,391212,643 and 144,892,202,479, respectively were included in the computation of diluted net income per common share amount as their impact were dilutive.

We had outstanding stock options totaling 47,538 and RSUs totaling 16,784 that are not included in the computation of diluted net income per share as their effect would have been anti-dilutive for the three months ended September 30, 2023. We had average outstanding stock options totaling 37,869 and RSUs totaling 15,027 that are not considered in the computation of diluted net income per share as their effect would have been anti-dilutive for the nine months ended September 30, 2023.

 

We had outstanding stock options totaling 34,211 that are not considered in the computation of diluted net income per share as their effect would have been anti-dilutive for the three months ended September 30, 2022. We had average outstanding stock options totaling 44,070 that are not considered in the computation of diluted net income per share as their effect would have been anti-dilutive for the nine months ended September 30, 2022. Outstanding stock options totaling 0 and 221 are not considered in the computation of diluted net income per share for the three and nine months ended September 30, 2021, respectively.

 

Restricted Cash

Cash and cash equivalents classified as restricted cash on our consolidated balance sheets are restricted as to withdrawal or use under the terms of certain contractual agreements. As of September 30, 2022,2023, we had outstanding letters of credit for $400.$300. Restricted cash as of September 30, 2023 was $422. The September 30, 2023 and December 31, 2022 was $792, which includesrestricted cash balance included lockbox deposits that are temporarily restricted due to timing at the period end. The lockbox deposits are applied against our line of credit the next business day.

 

10

Accounts Receivable and Allowance for Doubtful Accounts

Credit is extended based upon an evaluation of the customer’s financial condition and, while collateral is not required, the Company periodically receives surety bonds that guarantee payment. Credit terms are consistent with industry standards and practices. Trade accounts receivable have been reduced by

Allowance for Credit Losses

When we record customer receivables and contract assets arising from revenue transactions, we record an allowance for doubtful accountscredit losses for the current expected credit losses (CECL) inherent in the asset over its expected life. The allowance for credit losses is a valuation account deducted from the cost basis of $257the assets to present their net carrying value at September 30, 2022 and $328 at December 31, 2021.the amount expected to be collected. Each period, the allowance for credit losses is adjusted through earnings to reflect expected credit losses over the remaining lives of the assets.

 


We estimate expected credit losses based on relevant information about past events, including historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. When measuring expected credit losses, we pool assets with similar country risk and credit risk characteristics. Changes in the relevant information may significantly affect the estimates of expected credit losses.

Assets are written off when we determine them to be uncollectible. Write-offs are recognized as a deduction from the allowance for credit losses.

 

Inventories

Inventories are stated at the lower of average cost (which approximates first-in, first out) or net realizable value. Costs include material, labor, and overhead required in the warehousing and production of our products. Inventory reserves are maintained for the estimated value of the inventories that may have a lower value than stated or quantities in excess of future production needs.

 

Inventories are as follows:

 

 

September 30,

 

December 31,

  

September 30,

 

December 31,

 
 

2022

  

2021

  

2023

  

2022

 

Raw Materials

 $22,520  $18,492  $20,551  $21,673 

Work in Process

 1,719  1,678  1,220  1,238 

Finished Goods

 615  562  828  671 

Reserves

  (1,244)  (1,298)  (1,132)  (1,144)
  

Total

 $23,610  $19,434  $21,467  $22,438 

11

 

Other Intangible Assets

Other intangible assets at September 30, 20222023 and December 31, 20212022 are as follows:

 

 

Customer

Relationships

 

Trade

Names

 

Patents

 

Total

  

Customer

Relationships

 

Patents

 

Total

 

Balance at January 1, 2021

 $507  $589  $77  $1,173 

Balance at January 1, 2022

 $360  $141  $501 

Additions

 -  -  64  64  -  71  71 

Amortization

 147  29  -  176   144   6   150 

Abandonment Loss

  -   560   -   560 

Balance at December 31, 2021

 360  -  141  501 

Additions

 -  -  43  43 

Balance at December 31, 2022

 216  206  422 

Amortization

  108   -   3   111   108   11   119 

Balance at September 30, 2022

 $252  $-  $181  $433 

Balance at September 30, 2023

 $108  $195  $303 

 

Intangible assets are amortized on a straight-line basis over their estimated useful lives. The weighted-average remaining amortization period of our in-use intangible assetassets is 2.11.1 years. In-processOf the patents are not amortized until the patent is received. Atvalue at September 30, 2022, patents totaling $96 had2023, $85 are being amortized and $110 are in process and a patent has not yet been received while $85 of patents were in-process.received.

 

Amortization expense of finite life intangible assets for the three and nine months ended September 30, 2023 was $39 and $119, respectively. Amortization expense of finite life intangible assets for the three and nine months ended September 30, 2022 was $40 and $111, respectively. Amortization expense for the three and nine months ended September 30, 2021 was $45 and $139, respectively.

11

 

Estimated future annual amortization expense (not including patents in process)process of $110) related to these assets is approximately as follows:

 

Year

 

Amount

  

Amount

 

Remainder of 2022

 $40 

2023

 159 

Remainder of 2023

 $40 

2024

 86  87 

2025

 14  14 

2026

 14 

Thereafter

  49   38 

Total

 $348  $193 

 

Adoption of New Accounting Pronouncements Issued But Not Yet AdoptedStandards

In June 2016, the FASB issued ASU 2016-13, Measurement ofFinancial Instruments – Credit Losses on Financial Instruments. This guidance(Topic 326). The ASU introduces a new model for recognizingcredit loss methodology, Current Expected Credit Losses (CECL), which requires earlier recognition of credit losses, onwhile also providing additional transparency about credit risk.

The CECL methodology utilizes a lifetime “expected credit loss” measurement objective for the recognition of credit losses for loans, held-to-maturity securities and other receivables at the time the financial instruments based on an estimate of currentasses is originated or acquired. The expected credit losses are adjusted each period for changes in expected lifetime credit losses. The ASU also provides updatedmethodology replaces the multiple existing impairment methods in current GAAP, which generally require that a loss be incurred before it is recognized.

12

On January 1, 2023, we adopted the guidance regardingprospectively with a cumulative adjustment to retained earnings. We have not restated comparative information for 2022 and, therefore, the impairmentcomparative information for 2022 is reported under the old model and is not comparable to the information presented for 2023.

At adoption, we recognized an allowance for credit losses related to accounts receivable and contract assets of available-for-sale debt securities$30, net of tax, and includes additional disclosure requirements. a decrease in retained earnings of $30 associated with the increased estimated credit losses.

Revision and Immaterial Correction of an Error in Previously Issued Financial Statements

The new guidance is effective for public business entities that meetCompany identified an error related to the definitionclassification of a Smaller Reporting Company as defined by the SEC for interim and annual periods beginning after December 15, 2022. Early adoption is permitted. We are currently evaluating the impact of this standardactivity on our line of credit facility with Bank of America at December 31, 2022 as reported on Form 10-K. In our September 30, 2022 condensed consolidated financial statements, we incorrectly classified borrowings and related disclosures.payments on our line of credit facility on a net basis within the financing section of the condensed consolidated cash flow statement; this activity should be shown on a gross basis. This change in presentation to the condensed consolidated cash flow statement does not impact total operating, investing, or financing cash flows. There was no change to the condensed consolidated statement of income or condensed consolidated balance sheet. In accordance with ASC 250, Accounting Changes and Error Corrections, we evaluated the materiality of the errors from quantitative and qualitative perspectives and concluded that the errors were immaterial to the Company’s 2022 audited financial statements. Since these revisions were not material to any prior period financial statements, no amendments to previously filed financial statements are required. Consequently, the Company has corrected these immaterial errors by revising the September 30, 2022 consolidated financial statements presented herein.

 

The tables below present the effect of the financial statement adjustments related to the revision discussed above of the Company’s previously reported financial statements as of and for the period ended September 30, 2022:

Condensed Consolidated Statements of Cash Flows

         
             
  

September 30, 2022

 

CASH FLOWS FROM FINANCING ACTIVITIES

 

As reported

  

Adjustment

  

As revised

 

Net Proceeds from Line of Credit

  857   (857)  - 

Proceeds from Line of Credit

  -   88,673   88,673 

Payments to Line of Credit

  -   (87,816)  (87,816)

Principal Payments on Long-Term Debt

  -   -   - 

Principal Payments on Financing Leases

  (326)  -   (326)

Stock Option Exercises

  51   -   51 

Net Cash Provided by Financing Activities

  582   -   582 

13

 

 

NOTE 2. CONCENTRATION OF CREDIT RISK AND MAJOR CUSTOMERS

 

Financial instruments that potentially subject us to concentrations of credit risk consist principally of cash, accounts receivable, and accounts receivable.contract assets. With regard to cash, we maintain our excess cash balances in checking accounts at primarily two financial institutions, one in the United States and one in China. The account in the United States may at times exceed federally insured limits. Of the $2,092$699 in cash and restricted cash at September 30, 2022,2023, approximately $561$640 and $11$45 was held at banks located in China and Mexico, respectively. We grant credit to customers in the normal course of business and do not require collateral on our accounts receivable.

 

We have certain customers whose revenue individually represented 10% or more of net sales, or whose accounts receivable balances individually represented 10% or more of totalgross accounts receivable. Two customers accounted for 36% and 38% of net sales for the three and nine months ended September 30, 2023. One customer accounted for 28% and 26% of net sales for the three and nine months ended September 30, 2022, respectively. For the three months ended

At September 30, 2021,2023, two customers represented approximately 37% of our gross accounts receivable. At December 31, 2022, one customer represented approximately 21% of our gross accounts receivable.

Contract assets for two customers accounted for 36%29% of net sales. Forgross contract assets at September 30, 2023. Contract assets for one customer accounted for 22% of gross contract assets at December 31, 2022, respectively.

Export sales represented approximately 3% for both the three and nine months ended September 30, 2021, one customer accounted for 26% of net sales.

At September 30, 2022, two customers represented approximately 43% of our total accounts receivable. At December 31, 2021, one customer represented approximately 19% of our total accounts receivable.

2023. Export sales represented approximately 4% of net sales for both the three and nine months ended September 30, 2022. Export sales represented approximately 3% of net sales for the three and nine months ended September 30, 2021 respectively.

 


14

 

 

NOTE 3. REVENUE

 

Revenue recognition

Our revenue is comprised of product, engineering services and repair services. All revenue is recognized when the Company satisfies its performance obligation(s) under the contract by transferring the promised product or service to our customer either when (or as) our customer obtains control of the product or service, with the majority of our revenue being recognized over time including goods produced under contract manufacturing agreements and services revenue. A performance obligation is a promise in a contract to transfer a distinct product or service to a customer. A contract’s transaction price is allocated to each distinct performance obligation. The majority of our contracts have a single performance obligation, as the promise to transfer products or services is not separately identifiable from other promises in the contract and, therefore, not distinct.

 

Revenue is measured as the amount of consideration we expect to receive in exchange for transferring products or providing services. As such, revenue is recorded net of returns, allowances and customer discounts. Sales, value add, and other taxes collected from customers and remitted to governmental authorities are accounted for on a net (excluded from revenues) basis. Shipping and handling costs are included in cost of goods sold.

 

The majority of our revenue is derived from the transfer of goods produced under contract manufacturing agreements which have no alternative use and we have an enforceable right to payment for our performance completed to date. Our performance obligations within our contract manufacturing agreements are generally satisfied over time as the goods are produced based on customer specifications and we have an enforceable right to payment for the goods produced. Revenues under these agreements are generally recognized over time using an input measure based upon the proportion of actual costs incurred. If these requirements are not met, the revenue is recognized at a point in time, generally upon shipment. Revenue under contract manufacturing agreements that was recognized over time accounted for approximately 74% of our revenuenet sales for both the three and nine months ended September 30, 20222023, and 82% and 80% of our revenue forboth the three and nine months ended September 30, 2021, respectively. Revenues under these agreements are generally recognized over time using an input measure based upon the proportion of actual costs incurred.2022.

 

Accounting for contract manufacturing agreements involves the use of various techniques to estimate total revenue and costs. We estimate profit on these agreements as the difference between total estimated revenue and expected costs to complete the performance obligation within the terms of the agreement and recognize the respective profit as the goods are produced. The estimates to determine the profit earned on the performance obligation are based on anticipated selling prices and historical cost of goods sold and represent our best judgement at the time. Changes in judgements on these above estimates could impact the timing and amount of revenue recognized with a resulting impact on the timing and amount of associated profit.

 

On occasion our customers provide materials to be used in the manufacturing process and the fair value of the materials is included in revenue as noncash consideration at the point in time when the manufacturing process commences along with the same corresponding amount recorded as cost of goods sold. The inclusion of noncash consideration has no impact on overall profitability.

 


15

 

Contract Assets

Contract assets, recorded as such in the Condensed Consolidated Balance Sheets,Sheet, consist of unbilled amounts related to revenue recognized over time. Significant changes in the contract assets balance during the nine months ended September 30, 20222023 was as follows (in thousands):

 

Balance outstanding at December 31, 2021

 $8,698 

Balance outstanding at December 31, 2022

 $9,982 

Increase (decrease) attributed to:

  

Amounts transferred over time to contract assets

 72,536   76,225 

Allowance for current expected credit losses

 (22)

Amounts invoiced during the period

  (71,348)  (74,439)

Balance outstanding at September 30, 2022

 $9,886 

Balance outstanding at September 30, 2023

 $11,746 

 

We expect substantially all of the remaining performance obligations for the contract assets recorded as of September 30, 20222023, to be transferred to receivables within 90 days, with the majority of any remaining amounts to be transferred within 180 days. We bill our customers upon shipment with payment terms of up to 120 days.

 

The following tables summarize our net sales by timing of transfer of goodsmarket for the three months ended September 30, 2023 and services by market:2022, respectively:

  

Three Months Ended September 30, 2023

 
  

Product/ Service

Transferred Over

Time

  

Product

Transferred at

Point in Time

  

Noncash

Consideration

  

Total Net Sales by

Market

 

Medical

 $12,029  $5,185  $621  $17,835 

Industrial

  8,195   1,999   241   10,435 

Aerospace and Defense

  4,609   450   40   5,099 

Total net sales

 $24,833  $7,634  $902  $33,369 

 

  

Three Months Ended September 30, 2022

 
  

Product/ Service

Transferred Over

Time

  

Product

Transferred at

Point in Time

  

Noncash

Consideration

  

Total Net Sales by

Market

 

Medical

 $14,753  $5,366  $420  $20,539 

Industrial

  8,104   2,314   420   10,838 

Aerospace and Defense

  3,202   493   204   3,899 

Total net sales

 $26,059  $8,173  $1,044  $35,276 

 

  

Nine Months Ended September 30, 2022

 
  

Product/ Service

Transferred Over

Time

  

Product

Transferred at

Point in Time

  

Noncash

Consideration

  

Total Net Sales by

Market

 

Medical

 $37,725  $15,044  $1,574  $54,343 

Industrial

  21,563   6,301   1,095   28,959 

Aerospace and Defense

  13,248   1,254   701   15,203 

Total net sales

 $72,536  $22,599  $3,370  $98,505 

1416

 

  

Three Months Ended September 30, 2021

 
  

Product/ Service

Transferred Over

Time

  

Product

Transferred at

Point in Time

  

Noncash

Consideration

  

Total Net Sales by

Market

 

Medical

 $13,762  $2,933  $282  $16,977 

Industrial

  7,468   1,757   158   9,383 

Aerospace and Defense

  2,883   144   65   3,092 

Total net sales

 $24,113  $4,834  $505  $29,452 

The following tables summarize our net sales by market for the nine months ended September 30, 2023 and 2022, respectively:

 

 

Nine Months Ended September 30, 2021

  

Nine Months Ended September 30, 2023

 
 

Product/ Service

Transferred Over

Time

 

Product

Transferred at

Point in Time

 

Noncash

Consideration

 

Total Net Sales by

Market

  

Product/ Service

Transferred Over

Time

 

Product

Transferred at

Point in Time

 

Noncash

Consideration

 

Total Net Sales by

Market

 

Medical

 $35,497  $8,876  $1,017  $45,390  $42,324  $15,564  $1,926  $59,814 

Industrial

 20,385  4,832  560  25,777  21,378  6,532  1,056  28,966 

Aerospace and Defense

  9,685  527  327  10,539   12,523  1,674  301  14,498 

Total net sales

 $65,567  $14,235  $1,904  $81,706  $76,225  $23,770  $3,283  $103,278 

 

  

Nine Months Ended September 30, 2022

 
  

Product/ Service

Transferred Over

Time

  

Product

Transferred at

Point in Time

  

Noncash

Consideration

  

Total Net Sales by

Market

 

Medical

 $37,725  $15,044  $1,574  $54,343 

Industrial

  21,563   6,301   1,095   28,959 

Aerospace and Defense

  13,248   1,254   701   15,203 

Total net sales

 $72,536  $22,599  $3,370  $98,505 

 

 

NOTE 4. FINANCING ARRANGEMENTS

 

We have a credit agreement with Bank of America, which was entered into on June 15, 2017 and provides for a line of credit arrangement of $16,000 that expires on June 15, 2026.

 

Under the amended Bank of America credit agreement signed December 31, 2021, the line of credit is subject to variations in the Bloomberg Short-Term Bank Yield (BSBY) index rate. Our line of credit bears interest at a weighted-average interest rate of 4.1%8.2% and 3.5%5.2% as of September 30, 20222023 and December 31, 2021,2022, respectively. We had borrowings on our line of credit of $9,873$4,645 and $9,016$6,897 outstanding as of September 30, 20222023 and December 31, 2021,2022, respectively. There are no subjective acceleration clauses under the credit agreement that would accelerate the maturity of our outstanding borrowings. In addition, the credit agreement does not expire within one year, the Company is not in violation of the covenants and the Company expects Bank of America to be capable of honoring the financing arrangement. The line of credit is shown net of debt issuance costs of $48$34 and $58$44 on the condensed consolidated balance sheet for the periods ended September 30, 20222023 and December 31, 2021,2022, respectively.

 

The line of credit with Bank of America contains certain covenants which, among other things, require us to adhere to regular reporting requirements, abide by annual shareholder dividend limitations, maintain certain financial performance, and limit the amount of annual capital expenditures.

 

The Bank of America Credit Agreement provides for, among other things, a Fixed Charge Coverage Ratio of not less than 1.0 to 1.0, for the twelve months ended atending December 31, 2020 and each Fiscal Quarter end thereafter subject only during a trigger period commencing when our availability under our line is less than $2,000 until availability is above that amount for 30 days. As ofThe Company met the covenants for the period ended September 30, 2022 the Company was in compliance with its covenants.2023.

 

At September 30, 2022,2023, we had unused availability under our line of credit of $5,827$7,515 supported by our borrowing base. The line is secured by substantially all of our assets. In the first quarter of 2022, we amended our credit agreement to include the Employee Retention Credit Receivable as security in our line of credit which improved our unused availability. In the third quarter of 2022, we amended our credit agreement to extend the inclusion of the Employee Retention Credit Receivable through December 31, 2022.

 


17

 

 

NOTE 5. LEASES

 

We have operating leases for certain manufacturing sites, office space, and equipment. Most leases include the option to renew, with renewal terms that can extend the lease term from one to five years or more. Right-of-use lease assets and lease liabilities are recognized at the commencement date based on the present value of the remaining lease payments over the lease term which includes renewal periods we are reasonably certain to exercise. Our leases do not contain any material residual value guarantees or material restrictive covenants. At September 30, 2022,2023, we do not have material lease commitments that have not commenced.

 

The components of lease expense were as follows:

 

  

Three Months Ended September 30,

  

Three Months Ended September 30,

 

Lease Cost

 

2023

  

2022

 

Operating lease cost

 $576  $572 

Finance lease interest cost

  9   14 

Finance lease amortization expense

  182   182 

Total lease cost

 $767  $768 

 

 

Three Months Ended

September 30,

  

Three Months Ended

September 30,

  

Nine Months Ended

September 30,

  

Nine Months ended September 30,

 

Lease Cost

 

2022

  

2021

  

2023

  

2022

 

Operating lease cost

 $572  $576  $1,735  $1,731 
      

Finance lease interest cost

 14  18  32  50 
      

Finance lease amortization expense

  182   163   546   547 
        

Total lease cost

 $768  $757  $2,313  $2,328 

 

  

Nine Months Ended

September 30,

  

Nine Months ended

September 30,

 

Lease Cost

 

2022

  

2021

 

Operating lease cost

 $1,731  $1,696 
         

Finance lease interest cost

  50   61 
         

Finance lease amortization expense

  547   489 
         

Total lease cost

 $2,328  $2,246 

18

 

Supplemental balance sheet information related to leases was as follows:

 

Balance Sheet Location

 

September 30, 2022

  

December 31, 2021

 

Assets

         

Operating lease assets

Operating lease assets

 $8,079  $8,983 

Finance lease assets

Property, plant and equipment

  1,505   2,052 
         

Total leased assets

 $9,584  $11,035 

 

16

 

Balance Sheet Location

 

September 30, 2023

  

December 31, 2022

 

Assets

         

Operating lease assets

Operating lease assets

 $6,955  $7,850 

Finance lease assets

Property, Plant and Equipment

  817   1,363 

Total leased assets

 $7,772  $9,213 

 

Supplemental cash flow information related to leases was as follows:

 

 

September 30,

  

September 30,

  

September 30,

  

September 30,

 
 

2022

  

2021

  

2023

  

2022

 

Operating leases

            

Cash paid for amounts included in the measurement of lease liabilities

 $1,279  $861  $1,381  $1,279 

Right-of-use assets obtained in exchange for lease obligations

 $-  $858 

 

Maturities of lease liabilities were as follows:

 

 

Operating

Leases

 

Finance Leases

 

Total

  

Operating

Leases

 

Finance

Leases

 

Total

 

Remaining 2022

 $430  $126  $556 

2023

 1,765  409  2,175 

Remaining 2023

 $434  $108  $542 

2024

 1,505  357  1,861  1,514  379  1,893 

2025

 1,255  103  1,358  1,265  106  1,371 

2026

 1,217  108  1,332  1,227  107  1,334 

Thereafter

  7,066  -  7,066 

2027

 1,256  -  1,256 

Therafter

  5,817  -  5,817 

Total lease payments

 $13,238  $1,103  $14,341  $11,513  $700  $12,213 

Less: Interest

  (4,328

)

 (74) (4,402

)

  (3,682

)

 (38) (3,720

)

Present value of lease liabilities

 $8,910  $1,029  $9,939  $7,831  $662  $8,493 

 

The lease term and discount rate at September 30, 20222023 were as follows:

 

Weighted-average remaining lease term (years)

    

Operating leases

  9.18.7 

Finance leases

  2.82.0 

Weighted-average discount rate

    

Operating leases

  7.77.8

%

Finance leases

  5.25.3

%

 


19

 

 

NOTE 6. INCOME TAXES

 

On a quarterly basis, we estimate what our effective tax rate will be for the full fiscal year and record a quarterly income tax provision based on the anticipated rate. As the year progresses, we refine our estimate based on the facts and circumstances, including discrete events, by each tax jurisdiction.

 

Our effective tax rate for the three and nine months ended September 30, 20222023 was 16%(21%) and 15%13%, respectively. TheOur effective tax rate for the three and nine months ended September 30, 20212022 was 26%16% and 23%15%, respectively. The primary drivers of the change in the effective tax rate are due to a change in the federal valuation allowance, a discrete item of non-qualified options exercised over book value, and the amount due from the IRS exam conclusion.

NOTE 7. RESTRUCTURING CHARGES

During the first nine months of 2021, we recorded restructuring charges of $319 related to the consolidation of our production facilities and closure of our Merrifield, Minnesota facility. We recognized a gain on the sale of assets related to the restructure of $93 and $176 for both the three and nine months ended September 30, 2021, respectively. There were no restructuring charges or amounts accruedmonth periods relates to the change in valuation allowance on the nine months ended September 30, 2022.United States deferred tax assets due to return to provision adjustments partially offset by increased taxes on foreign entities.

 

 

NOTE 8.7. EMPLOYEE RETENTION CREDIT

 

On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) was signed into law providing numerous tax provisions and other stimulus measures, including an employee retention credit (“ERC”), which is a refundable tax credit against certain employment taxes. The Taxpayer Certainty and Disaster Tax Relief Act of 2020 and the American Rescue Plan Act of 2021 extended and expanded the availability of the ERC.

 

AtAll ERC payments have been received as of September 30, 2022 and2023. At December 31, 2021,2022, the Company hashad ERC benefits of $5,209$2,650 within Employee Retention Credits Receivable on the condensed consolidated balance sheet.

 


20

 

 

NOTE 9.8. RELATED PARTY TRANSACTIONS

 

David Kunin, our Chairman, is a minority owner of Abilitech Medical, Inc. Mr. Kunin also was a consultant to Abilitech which relationship ended onthrough March 1, 2021. In the three and nine months ended September 30, 2022, Abilitech paid the Company $0 and $217, respectively, for the delivery of medical products. InNo payments were received for the three and nine months ended September 30, 2021,2023. We have assets recorded related to Abilitech paidincluding $226 of accounts receivable and inventory. Abilitech has ceased operations and therefore we do not believe that Abilitech will pay the Company $316for outstanding accounts receivable or for inventory and $1,056, respectively forwe have recorded a full reserve against the delivery of medical products.gross amounts. The Company believes that transactions with Abilitech are on terms comparable to those that the Company could reasonably expect in an arm's length transaction with an unrelated third party.

 

David Kunin, our Chairman, is a minority owner (less than 10%10%) of Marpe Technologies, LTD an early-stage medical device company dedicated to the early detection of skin cancer through full body scanners. Mr. Kunin is also a member of the Board of Directors of Marpe Technologies. The Company worked with Marpe Technologies to apply for a grant from the Israel-United States Binational Industrial Research and Development Foundation, a legal entity created by Agreement between the Government of the State of Israel and the Government of the United States of America (“BIRD Foundation”). The parties were successful in receiving approval for a $1,000 conditional grant. Under the terms of the BIRD Foundation grant, theThe Company and Marpe Technologies are towill each receive $500 from the BIRD Foundation and, among other obligations under the grant, each is required to contribute $500 to match grant funds from the BIRD Foundation. The Company will meet its obligation by providing certain services at cost or with respect to administrative services at no cost to Marpe Technologies. The total value of the Company’s contribution will not exceed $500;$500. Marpe is engaged in raising funds for its operations, which funds are necessary to pay for the Company has contributed $226 as of September 30, 2022.Company’s services beyond its contribution. The Company will receive a 10-year exclusive right to manufacture the products of Marpe Technologies. There can be no assurances that Marpe Technologies’ medical device operations will be commercially successful, that Marpe Technologies will be successful in raising additional funds to finance its operations or, if commercially successful, the Company will recouprecover the value of services provided to Marpe for which isif not fully paid.paid when the services are provided. The transactions between the Company and Marpe Technologies have been approved by the Audit Committee pursuant to the Company Related-Party Transactions Policy. During the three and nine months ended September 30, 2023 and 2022, we recognized revenue to Marpe Technologies of $66$163 and $182. During both the three and nine months ended September 30, 2021, we recognized revenue of $78.$182, respectively. The Company believes that transactions with Marpe are on terms comparable to those that the Company could reasonably expect in an arm’s length transaction with an unrelated third party.

 


21

 

 

ITEM 2. MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

Overview

 

We are a Minnesota, United States based full-service global EMS contract manufacturer in the Medical, Aerospace & Defense and Industrial markets offering a full range of value-added engineering, technical and manufacturing services and support including project management, design, testing, prototyping, manufacturing, supply chain management and post-market services. Our products are complex electromedical and electromechanical products including medical devices, wire and cable assemblies, printed circuit board assemblies, higher-level assemblies, and other box builds for a wide range of industries. We serve three major markets within the EMS industry: Aerospace and Defense, Medical, and the Industrial market, which includes industrial capital equipment, transportation, vision, agriculture, oil and gas. We maintain facilities in Bemidji, Blue Earth, Mankato, and Milaca, Minnesota; Monterrey, Mexico; and Suzhou, China. All of our facilities are certified to one or more of the ISO/AS standards, including 9001, AS9100 and 13485, with most having additional certifications based on the needs of the customers they serve.

 

Recent Developments

Global Pandemic

The COVID-19 pandemic continued to impact our business in the first nine months of 2022, primarily by continued supply chain disruptions and delays. The full extent to which COVID-19 will directly or indirectly impact our business, financial condition, and results of operations will depend on future developments that are highly uncertain and cannot be accurately predicted, including new information that may emerge concerning COVID-19, the actions taken to contain it or treat its impact and the economic impact on local, regional, national and international markets.

We will continue to assess the current and potential impacts of the COVID-19 pandemic on our business, financial condition, and results of operations. We actively manage our cash and working capital to preserve adequate liquidity and ensure that our business can continue to operate during these uncertain times.


Results of Operations

 

The following table presents statements of operations data as percentages of total net sales for the periods indicated:

 

 

Three Months Ended

 

Nine Months Ended

  

Three Months Ended

 

Nine Months Ended

 
 

September 30,

  

September 30,

  

September 30,

  

September 30,

 
 

2022

  

2021

  

2022

  

2021

  

2023

  

2022

  

2023

  

2022

 

Net Sales

 100.0

%

 100.0

%

 100.0

%

 100.0  100.0

%

 100.0

%

 100.0

%

 100.0

%

Cost of Goods Sold

  82.1   72.7   84.4   83.9   84.1   82.1   84.2   84.4 

Gross Profit

 17.9  27.3  15.6  16.1  15.9  17.9  15.8  15.6 
  

Selling Expenses

 2.7  1.5  2.8  2.1  2.8  2.7  2.7  2.8 

General and Administrative Expenses

 8.4  6.9  8.5  8.9  8.8  8.4  9.0  8.5 

R&D Expenses

 1.3  0.5  1.2  0.4 

Restructuring Charges

 -  0.1  -  0.4 

Research and Development Expenses

 0.9  1.3  0.9  1.2 

Gain on Sale of Property and Equipment

  -   (0.3)  -   (0.2)  0.0   0.0   0.0   0.0 

Income from Operations

 5.5  18.6  3.1  4.5  3.4  5.5  3.2  3.1 
  

Interest Expense

  (0.3)  (0.4)  (0.3)  (0.4)  (0.4)  (0.3)  (0.4)  (0.3)

Income Before Income Taxes

 5.2  18.2  2.8  4.2  3.0  5.2  2.8  2.8 
  

Income Tax Expense

  0.8   4.2   0.4   0.8 

Income Tax (Benefit) Expense

  (0.6)  0.8   0.4   0.4 

Net Income

  4.4

%

  14.0

%

  2.4

%

  3.4

%

  3.6

%

  4.4

%

  2.4

%

  2.4

%

 

22

 

Net Sales

 

Net sales for the three months ended September 30, 2023 and 2022 were $33.4 million and 2021 were $35.3 and $29.5 million, respectively, an increasea decrease of $5.8$1.9 million or 19.7%5%. The decrease in net sales relates to demand fluctuations as customers work through inventory. The three months ended September 30, 2022 benefited from significant pricing actions ahead of material cost increases that contributed to record-high revenue in that period.

Net sales for the nine months ended September 30, 2023 and 2022 and 2021 were $98.5$103.3 million and $81.7$98.5 million, respectively, an increase of $16.8$4.8 million or 20.6%5%. The threeincrease in net sales is due to continued strong demand across our medical, industrial and nine month increases were driven by increased demand as well as price increases to counteract higher materialdefense market, and labor cost. We have alsothe impact of pricing actions taken actions to scalein the direct labor workforce and strengthen the supply chain for parts.second half of 2022.

 

Net sales by our major EMS industry markets for the three and nine months ended September 30, 20222023 and 20212022 were as follows (in millions):

 

  

Three Months Ended September 30,

  

Nine Months Ended September 30,

 
  

2022

  

2021

  

% Change

  

2022

  

2021

  

% Change

 

Medical

 $20.5  $17.0   20.6  $54.3  $45.4   19.6 

Industrial

  10.9   9.4   16.0   29.0   25.8   12.4 

Aerospace and Defense

  3.9   3.1   25.8   15.2   10.5   44.8 

Total Net Sales

 $35.3  $29.5   19.7  $98.5  $81.7   20.6 

21

  

Three months Ended September 30,

  

Nine months Ended September 30,

 
  

2023

  

2022

  

% Change

  

2023

  

2022

  

% Change

 

Medical

 $17.8  $20.5   (13.2) $59.8  $54.3   10.1 

Industrial

  10.5   10.9   (3.7)  29.0   29.0   - 

Aerospace and Defense

  5.1   3.9   30.8   14.5   15.2   (4.6)

Total Net Sales

 $33.4  $35.3   (5.4) $103.3  $98.5   4.9 

 

Backlog

 

Our 90-day ordershipment backlog as of September 30, 20222023 was $36.9$33.8 million, a 2.8% increase1% decrease from the beginning of the quarter and a 5.1%8% decrease from September 30, 2021.2022. Our 90-day backlog consists of firm purchase orders we expect to ship in the next 90 days, with any remaining amounts to be transferredshipped within 180 days.

 

Our 90-day order backlog by market has remained relatively constantdecreased when compared to the prior quarter end and the same period of the prior year. As the supply chain continues to normalize, lead times are reducing and customers are starting to return to their pre-pandemic ordering practices 90-day backlog varies due to order size, manufacturing delays, contract terms and conditions and timing from customer delivery schedules and releases. These variables cause inconsistencies in comparing the backlog from one period to the next.

 

23

90-day shipment backlog by our major industry markets are as follows (in millions):

 

  

90 Day Backlog as of the Period Ended

 
  

September 30

  

June 30

  

September 30

 
  

2022

  

2022

  

2021

 

Medical

 $22.8  $20.9  $19.7 

Industrial

  8.3   9.8   10.6 

Aerospace and Defense

  5.8   5.2   8.6 

Total 90-Day Backlog

 $36.9  $35.9  $38.9 

  

90 Day Backlog as of the Period Ended

 
  

September 30

  

June 30

  

September 30

 
  

2023

  

2023

  

2022

 

Medical

 $16.8  $18.3  $22.8 

Industrial

  9.7   9.7   8.3 

Aerospace and Defense

  7.3   6.3   5.8 

Total 90-Day Backlog

 $33.8  $34.3  $36.9 

 

Our total order backlog as of September 30, 20222023 was $103.3$102.3 million, a 2.7% decrease1% increase from $101.0 million the beginning of the quarter and a 31.4% increase1% decrease from September 30, 2021.2022. Our total backlog remains strong as our biggest customers are placing orders into the future to secure supply of critical components, in particular for those with long lead times.strong.

 

Total order backlog by our major industry markets are as follows (in millions):

 

  

Total Backlog as of the Period Ended

 
  

September 30

  

June 30

  

September 30

 
  

2022

  

2022

  

2021

 

Medical

 $58.4  $63.7  $37.3 

Industrial

  22.8   22.6   17.8 

Aerospace and Defense

  22.1   19.9   23.5 

Total Backlog

 $103.3  $106.2  $78.6 

  

Total Backlog as of the Period Ended

 
  

September 30

  

June 30

  

September 30

 
  

2023

  

2023

  

2022

 

Medical

 $51.4  $51.9  $58.4 

Industrial

 

19.7

   21.0   22.8 

Aerospace and Defense

  31.2   28.1   22.1 

Total Backlog

 $102.3  $101.0  $103.3 

 

The 90-day and total backlog at September 30, 20222023 contain the contract asset value of $9.9$11.7 million which has been recognized as revenue.

22

 

Gross Profit

 

Gross profit as a percent of net sales was 17.9%15.9% and 27.3%15.8% for the three and nine months ended September 30, 2022 and 2021,2023, respectively. Gross profit as a percent of net sales was 15.6%17.9% and 16.1% for the nine months ended September 30, 2022 and 2021, respectively. The decrease in gross profit as a percent of net sales15.6% for the three and nine months ended September 30, 2022, respectively. The decrease in gross profit as a percentage of net sales for the three months ended September 30, 2023 compared to the same periods in 2021 is primarily dueperiod of the prior year relates to the $4.7 million reduction in payroll and medical expenses related to the ERC in 2021, partially offset by price increases in response todecreased plant utilization, product mix, as well as continued material and labor cost inflation and higher production volume which increased plant utilization.inflation.

 

Selling Expense

 

Selling expenses for the three months ended September 30, 2022 and 2021 were $1.0 million or 2.7% of sales and $0.4 million or 1.5% of sales, respectively. Selling expenses for the nine months ended September 30, 2022 and 20212023 were $2.8$0.9 million or 2.8% of sales and $1.7$2.8 million or 2.1%2.7% of sales, respectively. Selling expense for the three and nine months ended September 30, 2021 includes a $0.1 million reduction in payroll and medical expenses related to the ERC. The increase in selling expense for the three and nine months ended September 30, 2022 compared to the same periodswere $1.0 million or 2.7% of the prior year relates to an increase in sales engineering expenses to support the increased sales.and $2.8 million or 2.8% of sales, respectively.

24

 

General and Administrative Expense

 

General and administrative expenses for the three months ended September 30, 2022 and 2021 were $2.9 million or 8.4% of sales and $2.0 million or 6.9% of sales, respectively. General and administrative expenses for the nine months ended September 30, 2022 and 20212023 were $8.3$3.0 million or 8.5%8.9% of sales and $7.2$9.3 million or 8.9%9.0% of sales, respectively. General and administrative expenses for the three and nine months ended September 30, 2021 includes a $0.42022 were $2.9 million reductionor 8.4% of net sales and $8.3 million or 8.5% of net sales, respectively. The increase in payroll and medical expenses related to the ERC. Generalgeneral and administrative expenses for the threeexpense was mainly due to higher wages and nine months ended September 30, 2022 were otherwise held relatively flat compared to the same periods of the prior year, and are generally fixed in nature.

Restructuring Charges

Restructuring charges for the three and nine months ended September 30, 2021 were $23 thousand and $0.3 million, respectively. There were no restructuring charges for the three and nine months ended September 30, 2022. The restructuring charges relate to the closure of the Merrifield facility during 2021.professional fees.

 

Research and Development Expense

 

Research and development expenses were $0.5 million or 1.3% of net sales for the three months ended September 30, 2022 and $1.2 million or 1.2% of net sales for the nine months ended September 30, 2022. Research and development expenses for the three and nine months ended September 30, 20212023 were $0.1$0.3 or 0.9% of net sales and $0.3$0.9 million or 0.9% of net sales, respectively. Research and development expenses for the three and nine months ended September 30, 2022 were $0.5 or 1.3% of net sales and $1.2 million or 1.2% of net sales, respectively.

23

 

Income From Operations

 

Income from operations for the three months ended September 30, 2022 was $1.9$1.1 million compared to $4.9and $3.3 million for the three months ended September 30, 2021. Income from operations for both theand nine months ended September 30, 20222023, respectively. Income from operations was $1.9 million and 2021 was $3.1 million.million for the three and nine months ended September 30, 2022. The decrease in income from operations for the comparable three months ended September 30, 2022 comparedmonth periods relates to the same perioddecreased revenue and gross margin in 2021 is primarily due to the $5.2 million reduction in payroll and medical expenses related to the ERC in 2021, partially offset by the increased gross profit in 2022.third quarter of 2023.

 

Interest Expense

 

Interest expense was $0.1 million for both the three months ended September 30, 20222023 and 2021.2022. Interest expense was $0.4 and $0.3 million for both the nine months ended September 30, 2023 and 2022, and 2021.respectively.

 

Income Taxes

 

On a quarterly basis, we estimate what our effective tax rate will be for the full fiscal year and record a quarterly income tax provision based on the anticipated rate. As the year progresses, we refine our estimate based on the facts and circumstances, including discrete events, by each tax jurisdiction.

 

Our effective tax rate for the three and nine months ended September 30, 20222023 was 16%(21%) and 15%13%, respectively. TheOur effective tax rate for the three and nine months ended September 30, 20212022 was 26%16% and 23%15%, respectively. The primary drivers of the change in the effective tax rate are a releasefor both the three and nine month periods relates to the change in valuation allowance a discrete item of non-qualified options exercised over book value, andon the amountUnited States deferred tax assets due from the IRS exam conclusion.to return to provision adjustments partially offset by increased taxes on foreign entities.

 

Net Income

 

Net income for the three months ended September 30, 2023 was $1.2 million or $0.44 per basic common share and $0.42 per diluted common share. Net income for the three months ended September 30, 2022 was $1.5 million or $0.57 per basic common share and $0.53 per diluted common share. Net income for the three months ended September 30, 2021 was $3.6 million or $1.33 per basic common share and $1.24 per diluted common share. The decrease in net income for the three month period was driven by the decrease in sales and gross margin.

Net income for the nine months ended September 30, 2022 compared to the same period in 2021 is primarily due to the $5.22023 was $2.5 million reduction in payrollor $0.93 per basic and medical expenses related to the ERC in 2021, partially offset by the increased gross profit in 2022.$0.87 per diluted common share. Net income for the nine months ended September 30, 2022 was $2.4 million or $0.89 per basic common share and $0.83 per diluted common share. NetThe increase in net income for the nine months ended September 30, 2021month period was $2.2 million or $0.82 per basic common sharedriven by the higher revenue and $0.78 per diluted common share.lower effective tax rate.

25

 

Liquidity and Capital Resources

 

We believe that our existing financing arrangements, anticipated cash flows from operations funds expected to be received for the ERC and cash on hand will be sufficient to satisfy our working capital needs for the next twelve months, capital expenditures and debt repayments.

24

 

Credit Facility

 

We have a credit agreement with Bank of America, which was entered into on June 15, 2017 and provides for a line of credit arrangement of $16.0 million$16,000 that expires on June 15, 2026.

 

Under the amended Bank of America credit agreement signed December 31, 2021, the line of credit is subject to variations in the Bloomberg Short-Term Bank Yield (BSBY) index rate. Our line of credit bears interest at a weighted-average interest rate of 4.1%8.2% and 3.5%5.2% as of September 30, 20222023 and December 31, 2021,2022, respectively. We had borrowings on our line of credit of $9.9$4.6 million and $9.0$6.9 million outstanding as of September 30, 20222023 and December 31, 2021,2022, respectively. There are no subjective acceleration clauses under the credit agreement that would accelerate the maturity of our outstanding borrowings. The line of credit is shown net of debt issuance costs of $48$34 thousand and $58$44 thousand on the consolidated balance sheet for the periods ended September 30, 20222023 and December 31, 2021,2022, respectively.

 

The line of credit with Bank of America contains certain covenants which, among other things, require us to adhere to regular reporting requirements, abide by annual shareholder dividend limitations, maintain certain financial performance, and limit the amount of annual capital expenditures.

 

The Bank of America Credit Agreement provides for, among other things, a Fixed Charge Coverage Ratio of not less than 1.0 to 1.0, for the twelve months ended atending December 31, 2020 and each Fiscal Quarter end thereafter subject only during a trigger period commencing when our availability under our line is less than $2.0 million until availability is above that amount for 30 days. As ofThe Company met the covenants for the period ended September 30, 2022 the Company was in compliance with its covenants.2023.

 

At September 30, 2022,2023, we had unused availability under our line of credit of $5.8$7.5 million supported by our borrowing base. The line is secured by substantially all of our assets. In the first quarter of 2022, we amended our credit agreement to include the Employee Retention Credit Receivable as security in our line of credit which improved our unused availability. In the third quarter of 2022, we amended our credit agreement to extend the inclusion of the Employee Retention Credit Receivable through December 31, 2022.

 

Off-Balance Sheet Arrangements

 

We have not engaged in any off-balance sheet activities as defined in Item 303(a)(4) of Regulation S-K.

 

Critical Accounting Policies and Estimates

 

Our significant accounting policies and estimates are summarized in Management’s Discussion and Analysis of Financial Condition and Results of Operations in our Annual Report on Form 10-K for the year ended December 31, 2021.2022. Some of our accounting policies require us to exercise significant judgment in selecting the appropriate assumptions for calculating financial estimates. Such judgments are subject to an inherent degree of uncertainty. These judgments are based on our historical experience, known trends in our industry, terms of existing contracts and other information from outside sources, as appropriate. Actual results could differ from these estimates.

 

2526

 

Forward-Looking Statements

 

Those statements in the foregoing report that are not historical facts are forward-looking statements made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995.

 

 

Volatility in the marketplace which may affect market supply, demand of our products labor rates or currency exchange rates;

 

Supply chain disruption and unreliability;

 

Lack of supply of sufficient human resources to produce our products;

 

Increased competition from within the EMS industry or the decision of OEMs to cease or limit outsourcing;

 

Changes in the reliability and efficiency of our operating facilities or those of third parties;

 

Increases in certain raw material costs such as copper and oil;

 

Commodity and energy cost instability;

 

Risks related to FDA noncompliance;

 

The loss of a major customer;

 

General economic, financial and business conditions that could affect our financial condition and results of operations;

 

Increased or unanticipated costs related to compliance with securities and environmental regulation;

 

Disruption of global or local information management systems due to natural disaster or cyber-security incident;

 

Outbreaks of epidemic, pandemic, or contagious diseases, such as the recent novel coronavirus that affect our operations, our customers' operations or our suppliers' operations.

 

The factors identified above are believed to be important factors (but not necessarily all of the important factors) that could cause actual results to differ materially from those expressed in any forward-looking statement made by us. Discussion of these factors is also incorporated in Part I, Item 1A, “Risk Factors,” and should be considered an integral part of Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” of our Annual Report on Form 10-K for the fiscal year ended December 31, 2021.Operations.” Unpredictable or unknown factors not discussed herein could also have material adverse effects on forward-looking statements. All forward-looking statements included or incorporated intoin this Form 10-Q10-K are expressly qualified in their entirety by the forgoing cautionary statements. We undertake no obligations to update publicly any forward-looking statement (or its associated cautionary language) whether as a result of new information or future events.

 

Please refer to forward-looking statements and risks as previously disclosed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021.2022.

 

2627

ITEM 3.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

Not applicable.

ITEM 4.

ITEM 4. CONTROLS AND PROCEDURES

 

Evaluation of Disclosure Controls and Procedures

In accordance with Rule 13a-15(b) of the Securities Exchange Act of 1934 (the “Exchange Act”), as of the end of the period covered by this Quarterly Report on Form 10-Q, our management evaluated, with the participation of our Chief Executive Officer and Chief Financial Officer, the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rule 13a-15(e) and Rule 15d-15(e) under the Exchange Act). These controls and procedures are designed to ensure that information required to be disclosed in the Company’s Exchange Act reports is (1) recorded, processed, summarized and reported in a timely manner, and (2) accumulated and communicated to management, including the Company’s Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. Based upon their evaluation of these disclosure controls and procedures as of the date of the evaluation, the Chief Executive Officer and Chief Financial Officer concluded that the disclosure controls and procedures were effective.

 

Changes in Internal Control Over Financial Reporting

 

There was no change in our internal control over financial reporting during our most recently completed fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

 


28

 

PART II

ITEM 1.

ITEM 1. LEGAL PROCEEDINGS

 

We are subject to various legal proceedings and claims that arise in the ordinary course of business.

ITEM 1A.

ITEM 1A. RISK FACTORS

 

We are affected by the risks specific to us as well as factors that affect all businesses operating in a global market. The significant factors known to us that could materially adversely affect our business, financial condition or operating results or could cause our actual results to differ materially from our expectations are described in our annual report on Form 10-K for the fiscal year ended under the heading “Part I – Item 1A.Risk Factors.” There have been no material changes in the risk factors from those disclosed in the Annual Report on Form 10-K for the year ended December 31, 2021.2022.

ITEM 2.

UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

 

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

As of September 30, 2022, ourOur share repurchase program has expired, and no additional amounts are available for repurchase.

ITEM 3.

ITEM 3. DEFAULTS ON SENIOR SECURITIES

 

None.

ITEM 4.

ITEM 4. MINE SAFETY DISCLOSURES

 

Not applicable.

ITEM 5.

ITEM 5. OTHER INFORMATION

 

None.

 


29

ITEM 6.

ITEM 6. EXHIBITS

 

Exhibits

 

31.1*

Certification of the Chief Executive Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a), promulgated under the Securities Exchange Act of 1934, as amended.

 

 

31.2*

Certification of the Chief Financial Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a), promulgated under the Securities Exchange Act of 1934, as amended.

 

 

32*

Certification of the Chief Executive Officer and Chief Financial Officer, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

 

 

101*

Financial statements from the quarterly report on Form 10-Q for the quarter ended September 30, 2022,2023, formatted in Inlineinline XBRL: (i) Condensed Consolidated Balance Sheets, (ii) Condensed Consolidated Statements of Operations and Comprehensive Loss, (iii) Condensed Consolidated Statements of Cash Flows, and (iv) the Condensed Notes to Condensed Consolidated Financial Statements.

 

 

104

Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

   

105*

Eighth Amendment dated September 1, 2022 to Loan and Security Agreement between the Company and Bank of America N.A.

      

*Filed herewith

 


30

 

Signatures

---------------------------

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

 

Nortech Systems Incorporated and Subsidiaries

--------------------------------------------------------------------------------------------------------------------

 

 

Date:  November 9, 2022     

14, 2023

by:

by

/s/ Jay D. Miller

   

Jay D. Miller

Chief Executive Officer and President

  Nortech Systems Incorporated

Date:  November 9, 2022     

14, 2023

by:

by

/s/ Christopher D. JonesAlan K. Nordstrom

   

Christopher D. Jones

Vice President and

Alan K. Nordstrom
Acting Chief Financial Officer

and Corporate Controller
  Nortech Systems Incorporated

 

3031